The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 15, 2015

Filed:

Mar. 15, 2013
Applicant:

Noven Therapeutics, Llc, Miami, FL (US);

Inventors:

David A. Engers, West Lafayette, IN (US);

Yonglai Yang, West Lafayette, IN (US);

Stephan Parent, West Lafayette, IN (US);

Travis Houston, West Lafayette, IN (US);

Bruce Charles Friedman, New York, NY (US);

Assignee:

NOVEN THERAPEUTICS, LLC, Miami, FL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4525 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 9/19 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4525 (2013.01); A61K 9/1635 (2013.01); A61K 9/4866 (2013.01); A61K 9/19 (2013.01);
Abstract

The invention relates to solid dispersions containing paroxetine mesylate. One solid dispersion contains amorphous paroxetine mesylate and a methacrylic acid-methyl methacrylate copolymer, where the weight ratio of paroxetine mesylate to polymer ranges from about 30:70 to about 90:10. Another solid dispersion contains amorphous paroxetine mesylate and a -vinylpyrrolidone/vinylacetate copolymer (PVP-VA), where the weight ratio of paroxetine mesylate to copolymer ranges from about 30:70 to about 50:50. An amorphous solid dispersion of the invention may have a single glass transition temperature. An amorphous solid dispersion is stable for at least 48 hours at 60° C. and 75% relative humidity. A further embodiment of the invention relates to pharmaceutical compositions of paroxetine mesylate comprising a solid dispersion of the invention and at least one pharmaceutically acceptable excipient. Methods for the treatment using paroxetine mesylate in the form of a solid dispersion according to the invention are also disclosed.


Find Patent Forward Citations

Loading…